Nanodropper is kicking off the new year with a new corporate identity as Mu Medical and expansion into a precision eyecare platform with two other companies: Bedo Solutions and Viseon Labs.
The new entity is formally debuting this week during the 44th annual J.P. Morgan Healthcare Conference week in San Francisco, California (Jan. 12–15, 2026).
Talk about a fresh start … let’s start with a rundown on Nanodropper.
Until this corporate update, Nanodropper had operated as a micro-volume ophthalmic delivery device company, providing solutions to adherence barriers for chronic ocular disease management.
Its namesake product: The Nanodropper Bottle Adaptor, a Class I medical device marketed as the only FDA-listed, volume-reducing adaptor for eye drop bottles.
And what do we know about those other two companies?
Bedo Solutions is known for developing drop administration aids to assist users with placing and delivering eye medications more accurately and comfortably.
- Among its offerings: GentleDrop, a multi-use, silicone eye drop delivery device that expands to fit most eye drop bottles and minimizes patient discomfort.
- Viseon Labs is an oculomics-focused medical technology company developing advanced monitoring and artificial intelligence (AI)-based solutions that track patient adherence and eye health outside of the clinical setting.
- Among its offerings: VuTRACK, which utilizes machine vision to enable adherence tracking and generate actionable health insights.
So why target Bedo and Viseon?
A major reason: All three companies were founded by physicians with similar clinical perspectives and patient-centered missions that seek to improve both access and outcomes, Nanodropper noted.
Those founders:
- Nandropper CEO: Allisa Song, MD
- Bedo CEO: Robert Kinast, MD
- Viseon CEO: Sina Fateh, MD
Now about this consolidation …
The planned merger is intended to turn Nanodropper from a (in its own words) “single-product device manufacturer” into a “broader commercial-stage medtech ecosystem.”
- Specifically: This involves integrating Bedo Solutions and Viseon Labs’ assets and intellectual property into Nanodropper’s existing infrastructure—with all three companies operating under the Mu Medical name.
The focus: Advancing precision and personalized eyecare.
Give me specifics.
Once united, Mu Medical will reportedly be organized into four product categories—each featuring targeted offerings that support its new medtech ecosystem.
Starting with the first two categories:
- Consumer devices: Patient-focused eye drop tools optimizing existing treatments
- Nanodropper Adaptor
- GentleDrop
- Primary packaging: Enabling precision dosing via proprietary micro-volume delivery (MVD) technologies.
- MuPACK-JT2 insert: A customized MVD tip for traditional three-piece squeeze-type bottles (available beginning March 2026)
- MuVEYE: A MVD single-use “unit dose” blow-fill seal packaging compatible with preservative-free formulations (available beginning December 2026)
- MuMIST: A cartridge-based, horizontal drug delivery system utilizing VuTrack monitoring as a precision delivery platform for topical ophthalmics (no availability details as of yet)
And the other two?
- Monitoring and oculomics
- VuTRACK: In development to be a leading platform in front-of-the-eye imaging for predicting, diagnosing, and monitoring ophthalmic and neurologic diseases
- AI therapeutics: Applying advanced analytics in support of personalized treatment via AI-based solutions.
- MyopiaAI
- VizGuard
According to MuMedical, it is currently developing “the first AI vision [biologically-based] algorithm to fight blindness-causing conditions” such as myopia.
And what’s happening to those three CEOs?
Mu Medical is being restructured with the following leadership:
- Dr. Song as CEO and Board Chair
- Dr. Fateh as Chief Strategy Officer and Board Observer
- Dr. Kinast as Board Observer and Medical Advisor
Let’s talk monetary details.
Unfortunately, there’s nothing to report on this front. In announcing its new identity, Mu Medical did not disclose any further information (not even a kernel).
Gotcha. Now the big question: Why make this move?
As new Mu Medical CEO Dr. Song noted, Nanodropper was looking to break the mold of a “one-size-fits-all” model that eyecare has traditionally operated under.
"By bringing Bedo Solutions and Viseon Labs into our ecosystem, we will be able to personalize the entire journey: from delivering the precise dose a patient needs to monitoring adherence at home and using [artificial intelligence] to tailor therapy in real time,” she stated.